Feb 13 (Reuters) - CSL Ltd (CSL) :
- FY24 NPATA ANTICIPATED TO BE IN RANGE OF APPROXIMATELY $2.9 BILLION TO $3.0 BILLION AT CC
- IN A STRONG POSITION TO DELIVER ANNUALISED DOUBLE-DIGIT EARNINGS GROWTH OVER MEDIUM TERM
- FOR CSL VIFOR, WELL PREPARED FOR THE TRANSITIONING IRON MARKET
- DUE TO SEASONALITY OF CSL SEQIRUS BUSINESS, ANTICIPATE IT TO POST A LOSS IN 2H OF FY24
- STRONG GROWTH IN IMMUNOGLOBULINS FRANCHISE EXPECTED TO CONTINUE AS PATIENT DEMAND REMAINS STRONG
- PLASMA INITIATIVES IMPLEMENTED ARE STARTING TO DRIVE GROSS MARGIN RECOVERY
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$257.38 |
Change
8.990(3.62%) |
Mkt cap ! $124.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $258.31 | $251.10 | $370.9M | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $257.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $257.38 | 3331 | 1 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |